119.95
+2.78(+2.37%)
Currency In USD
| Previous Close | 117.17 |
| Open | 118.09 |
| Day High | 121.3 |
| Day Low | 117.78 |
| 52-Week High | 121.62 |
| 52-Week Low | 29.17 |
| Volume | 3.61M |
| Average Volume | 3.11M |
| Market Cap | 23.19B |
| PE | -23.16 |
| EPS | -5.18 |
| Moving Average 50 Days | 76.25 |
| Moving Average 200 Days | 49.39 |
| Change | 2.78 |
If you invested $1000 in Revolution Medicines, Inc. (RVMD) since IPO date, it would be worth $4,150.52 as of January 14, 2026 at a share price of $119.95. Whereas If you bought $1000 worth of Revolution Medicines, Inc. (RVMD) shares 5 years ago, it would be worth $2,997.25 as of January 14, 2026 at a share price of $119.95.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Revolution Medicines Announces FDA Breakthrough Therapy Designation for Zoldonrasib
GlobeNewswire Inc.
Jan 08, 2026 1:00 PM GMT
Breakthrough Therapy Designation granted to zoldonrasib for the treatment of adult patients with KRAS G12D-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC) who have been previously treated with anti-PD-1/PD-L1 therapy and pla
Revolution Medicines to Present at 44th Annual J.P. Morgan Healthcare Conference
GlobeNewswire Inc.
Jan 05, 2026 9:05 PM GMT
REDWOOD CITY, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that Mark A. Goldsmith,
Revolution Medicines Announces First Patient Randomized in the RASolute 304 Clinical Trial of Daraxonrasib in Resectable Pancreatic Ductal Adenocarcinoma Following Adjuvant Chemotherapy
GlobeNewswire Inc.
Dec 18, 2025 1:00 PM GMT
REDWOOD CITY, Calif., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced the first patient has been randomized in the